AbCellera-Discovered Antibody Neutralizes Viral Variants of COVID-19; in Trials

- New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern

- LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting effectiveness against emerging variants

- LY-CoV1404 neutralizes authentic SARS-CoV-2 with high potency in vitro

- LY-CoV1404 enters clinical trials as part of Lilly’s BLAZE-4 study in patients with mild-to-moderate COVID-19 illness

https://finance.yahoo.com/news/abcellera-discovered-antibody-neutralizes-viral-103000927.html